It was a great pleasure to meet up with Marwan Sabbagh (Cleveland Clinic Lerner College of Medicine, Las Vegas, NV, USA), to discuss the recent approval of aducanumab for Alzheimer’s Disease. Aducanumab was granted accelerated approval on June 7 2021, by the U.S. Food and Drug Administration (FDA).
- Could you give us a brief overview of the clinical trial program that has led to the approval of aducanumab for Alzheimer’s disease? (0:09)
- Could you tell us more about the ongoing EMBARK study? (1:38)
- Why has aducanumab succeeded when so many other drugs have failed late stage clinical trials? (2:07)
- What are the challenges and opportunities presented by this approval? (4:01)
- What questions remain unanswered and what future studies are planned? (5:30)
Disclosures: Marwan Sabbagh receives research support from the NIH and the Keep Memory Alive Foundation; consulting agreements with Alzheon, Biogen, Cortexyme, Danone, Neurotrope, Regenron, Stage 2 Innovations, Acadia, and Roche-Genentech; stock options in Brain Health Inc., NeuroReserve, NeuroTau, Optimal Cognitive Health Co., uMethod Health,Versanum Inc. and Athira.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch
Share this Video
Related Videos In Alzheimer's Disease & Dementia
Kristian Steen Frederiksen, EAN 2023: The new EAN guidelines
Dr Kristian Steen Frederiksen (Danish Dementia Research Center, Denmark, Copenhagen) summarizes some of the key updates to the EAN guidelines, and the take-home messages presented at the annual European Academy of Neurology (EAN), July 1–4, 2023. Disclosures: Kristian Steen Frederiksen has no financial or non-financial conflicts of interest to declare in relation to this video. Support: Interview and filming was supported by Touch […]
Kristian Steen Frederiksen, EAN 2023: Highlights in Alzheimer’s disease and dementia
Dr Kristian Steen Frederiksen (Danish Dementia Research Center, Denmark, Copenhagen) discusses his highlights from the annual European Academy of Neurology (EAN), July 1–4, 2023 in the field of Alzheimer’s disease and dementia. Disclosures:Kristian Steen Frederiksen has no financial or non-financial conflicts of interest to declare in relation to this video. Support: Interview and filming was supported by Touch Medical Media. The interview was conducted by Sophie Nickelson. […]
Kristen George, AAIC 2022: Experiences of discrimination on cognitive function and ageing among the oldest old: The LifeAfter90 (LA90) Study
The LifeAfter90 (LA90) Study aims to understand what cognitive ageing and dementia look like among individuals aged 90 and above. In this interview, Dr Kristen George (University of California Davis School of Medicine, University of California, Davis, CA, USA) discussed what the study found in terms of the effect of discrimination on the cognitive function of this […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!